A Colgan High School senior was named one of the top 40 finalists in the 2025 Regeneron Science Talent Search, a prestigious ...
The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...
Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...
Investor's Business Daily on MSN8h
How Databricks Pounced On AI Opportunity Amid Snowflake, Palantir RivalriesThe rivalry between enterprise software makers Snowflake and Databricks intensified amid the emergence of generative ...
Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in ...
In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.
This was the stock's second consecutive day of losses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback